Company: XXII
Filing Date: 2025-11-04
Form Type: 424B5
Source: 0001493152-25-020754
Chunk: 5

Company: 22nd Century Group, Inc.
Filing Date: 2025-11-04
Form: 424B5
Chunk 5
---
 intended or their penetration by outside parties with the intent to corrupt them   
 could result in business disruption, litigation and regulatory action, and loss of revenue, assets, or personal or confidential data 
 (cybersecurity).                                                                                                                     |

| ● | We                                                                                                                      
 may be unsuccessful at commercializing our Very Low Nicotine “VLN” tobacco using the reduced exposure claims authorized 
 by the Food and Drug Administration (“FDA”).                                                                            |

| ● | The                                                                                                                                  
 manufacturing of tobacco products subjects us to significant governmental regulation and the failure to comply with such regulations 
 could have a material adverse effect on our business and subject us to substantial fines or other regulatory actions.                |

| ● | We                                                                                                                                
 may become subject to litigation related to cigarette smoking and/or exposure to environmental tobacco smoke, or ETS, which could 
 severely impair our results of operations and liquidity.                                                                          |

| ● | The                                                                                                                               
 loss of a significant customer for whom we manufacture tobacco products could have an adverse impact on our results of operation. |

| ● | Product                                                                                                     
 liability claims, product recalls, or other claims could cause us to incur losses or damage our reputation. |

| S-2 |

| ● | The                                                               
 FDA could force the removal of our products from the U.S. market. |

| ● | Certain                                                                                                                            
 of our proprietary rights have expired or may expire or may not otherwise adequately protect our intellectual property, products   
 and potential products, and if we cannot obtain adequate protection of our intellectual property, products and potential products, 
 we may not be able to successfully market our products and potential products.                                                     |

| ● | We                                                                                                                               
 license certain patent rights from third-party owners. If such owners do not properly maintain or enforce the patents underlying 
 such licenses, our competitive position and business prospects could be harmed.                                                  |

| ● | Our                                                            
 stock price may be highly volatile and could decline in value. |

| ● | We                                                                                                                                     
 are a named defendant in certain litigation matters; if we are unable to resolve these matters favorably, then our business, operating 
 results and financial condition may be adversely affected.                                                                             |

| ● | Future                                                                                                     
 conversion of the Series A convertible preferred stock will result in dilution to our common stockholders. |

| ● | We                                                                                    
 do not expect to declare any dividends on our common stock in the foreseeable future. |

You also should carefully review the risk factors and cautionary statements described in the other documents we file or furnish from time to time with the SEC, including